Skip to main content

Advertisement

SpringerLink
Log in

BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study

  • Gynecologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

A Correction to this article was published on 28 August 2018

This article has been updated

Abstract

Objective

The aim of this study was to assess the correlation between BRCA mutation status and disease presentation, treatment strategy, and survival in a multicenter series of recurrent high-grade serous ovarian cancer (HGSOC) women.

Methods

A consecutive series of recurrent HGSOC patients with partially or fully platinum-sensitive disease admitted to the Gynecologic Oncology Units of the Catholic University of the Sacred Heart and Sapienza University of Rome. Main eligibility criteria were known BRCA 1/2 germline mutation status and a minimum follow-up period from recurrence of at least 6 months.

Results

Overall, 126 patients met the eligibility criteria, of whom 76 (60%) were BRCA wild-type (BRCAwt) and 50 (40%) were BRCA 1/2 germline mutation carriers (BRCAmut). Among the latter, 37 (74%) patients presented with BRCA1 mutation, and 13 (26%) presented with BRCA2. No differences were found regarding patterns of disease presentation between BRCAwt and BRCAmut women. BRCAmut patients had the best post-recurrence survival (PRS) regardless of having received secondary cytoreductive surgery (SCS) or not, with a 5-year PRS of 73% in non-resected women versus 78% in resected women (p = 0.558). Conversely, BRCAwt patients who underwent complete SCS had a significantly longer PRS compared with BRCAwt patients who did not receive surgery (5-year PRS of 54% vs. 42%; p = 0.048).

Conclusions

Recurrent ovarian cancer BRCAmut patients have the best prognosis regardless of SCS, whereas PRS in BRCAwt women can improve when complete SCS is performed. The identification and incorporation of predictive biomarkers such as BRCA status to tailor the medical and surgical approach is paramount to the success of recurrent HGSOC treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

  • 28 August 2018

    In the original version of the article, Angelo Minucci’s last name was spelled incorrectly. It is correct as shown here. The original article has been corrected.

  • 28 August 2018

    In the original version of the article, Angelo Minucci?s last name was spelled incorrectly. It is correct as shown here. The original article has been corrected.

  • 28 August 2018

    In the original version of the article, Angelo Minucci?s last name was spelled incorrectly. It is correct as shown here. The original article has been corrected.

References

  1. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced- stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013; 10: 211–224.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–393.

    Article  CAS  PubMed  Google Scholar 

  3. Gallagher DJ, Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol. 2011; 22:1127–1132.

    Article  CAS  PubMed  Google Scholar 

  4. Petrillo M, Marchetti C, De Leo R, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017; 217(3): 334.e1–334.e9.

    Article  Google Scholar 

  5. Bookman MA, Tyczynski JE, Espirito JL,Wilson TW, Fernandes AW. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecol Oncol. 2017;146(1): 58–63.

    Article  CAS  PubMed  Google Scholar 

  6. Lorusso D, Scambia G, Pignata S, et al. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. Ann Oncol. 2016; 27(3):487–93.

    Article  CAS  PubMed  Google Scholar 

  7. Meehan RS, Chen AP. New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract. 2016;3:3.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Fagotti A, Fanfani F, Rossitto C, et al. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Oncology. 2008;75(3–4):152–8.

    Article  CAS  PubMed  Google Scholar 

  9. Fanfani F, Monterossi G, Fagotti A, et al. Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2015;22(2):649–54.

    Article  PubMed  Google Scholar 

  10. Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer. 2006;42(14):2296–302.

    Article  PubMed  Google Scholar 

  11. Zielinski CC, Pinto C. AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open. ESMO Open. 2016;1(4):e000080.

    Article  Google Scholar 

  12. Minucci A, Scambia G, Santonocito C, et al. Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: the experience at Gemelli hospital and a literature review. Expert Rev Mol Diagn. 2015;15(10):1383–403.

    Article  CAS  PubMed  Google Scholar 

  13. Balabanski L, Antov G, Dimova I, et al. Next-generation sequencing of BRCA1 and BRCA2 in breast cancer patients and control subjects. Mol Clin Oncol. 2014;2:435–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Concolino P, Rizza R, Hackmann K, et al. Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome. Breast Cancer Res Treat. 2017;164(2):497–503.

    Article  CAS  PubMed  Google Scholar 

  15. Concolino P, Costella A, Minucci A, et al. A preliminary quality control (QC) for next-generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations. Clin Chim Acta. 2014;437:72–7.

    Article  CAS  PubMed  Google Scholar 

  16. Capoluongo E, Ellison G, López-Guerrero JA, et al. Guidance statement on BRCA1/2 tumor testing in ovarian cancer patients. Semin Oncol. 2017;44(3):187–197.

    Article  CAS  PubMed  Google Scholar 

  17. Minucci A, De Paolis E, Concolino P, et al. Competitive PCR-High Resolution Melting Analysis (C-PCR-HRMA) for large genomic rearrangements (LGRs) detection: a new approach to assess quantitative status of BRCA1 gene in a reference laboratory. Clin Chim Acta. 2017;470:83–92.

    Article  CAS  PubMed  Google Scholar 

  18. Badoer C, Garrec C, Goossens D, et al. Performance of multiplicom’s BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples. Oncotarget. 2016;7(49):81357–81366.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Capoluongo E. BRCA to the future: towards best testing practice in the era of personalised healthcare. Eur J Hum Genet. 2016;24 Suppl 1:S1-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. BRCA Germline I Reference Standard gDNA. Available at: https://www.horizondiscovery.com/brca-germline-i-hd793.

  21. Petrillo M, Nero C, Amadio G, Gallo D, Fagotti A, Scambia G. Targeting the hallmarks of ovarian cancer: the big picture. Gynecol Oncol. 2016;142(1):176–183.

    Article  CAS  PubMed  Google Scholar 

  22. Fanfani F, Fagotti A, Gallotta V, et al. Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol Oncol. 2010;116(3):497–501.

    Article  PubMed  Google Scholar 

  23. Benedetti Panici P, De Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007; 14(3):1136–42.

    Article  PubMed  Google Scholar 

  24. Manci N, Bellati F, Muzii L, et al. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data. Ann Surg Oncol. 2006; 13(12):1717–23.

    Article  PubMed  Google Scholar 

  25. Lorusso D, Mancini M, Di Rocco R, Fontanelli R, Raspagliesi F. The role of secondary surgery in recurrent ovarian cancer. Int J Surg Oncol. 2012;2012:613980.

    CAS  Google Scholar 

  26. Du Bois A, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol. 2017; 35 Suppl: abstract no. 5501.

  27. Harter P, Du Bois A, Hahmann M, et al. Suregery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702–10.

    Article  PubMed  Google Scholar 

  28. Tian WJ, Chi DS, Sehouli J, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19:597–604.

    Article  PubMed  Google Scholar 

  29. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002;20:463–466.

    Article  CAS  PubMed  Google Scholar 

  30. Tan DS, Rothermundt C, Thomas K, et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26:5530–5536.

    Article  PubMed  Google Scholar 

  31. Concolino P, Rizza R, Hackmann K, et al. Identification and characterization of a new BRCA2 Rearrangement in an Italian family with hereditary breast and ovarian cancer syndrome. Mol Diagn Ther. 2017;21(5):539–545.

    Article  CAS  PubMed  Google Scholar 

  32. Wu X, Wu L, Kong B, et al. The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients. Int J Gynecol Cancer. 2017;27(8):1650–1657.

    Article  PubMed  Google Scholar 

  33. Eoh KJ, Kim JE, Park HS, et al. Detection of Germline mutations in patients with epithelial ovarian cancer using multi-gene panels: beyond BRCA1/2. Cancer Res Treat. 2018;50(3):917–925.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

None.

Author information

Authors and Affiliations

  1. Department of Gynecological-Obstetrical Sciences and Urological Sciences, Sapienza University of Rome, Rome, Italy

    Claudia Marchetti PhD, Angela Musella PhD & Pierluigi Benedetti Panici PhD

  2. Department of Woman and Child Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Roma, Italia

    Rossella De Leo MD, Marco D’Indinosante MD, Giovanni Scambia PhD & Anna Fagotti PhD

  3. Laboratory of Clinical Molecular and Personalized Diagnostics, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Roma, Italia

    Ettore Capoluongo PhD & Angelo Minucci PhD

Authors
  1. Claudia Marchetti PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rossella De Leo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angela Musella PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marco D’Indinosante MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ettore Capoluongo PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Angelo Minucci PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pierluigi Benedetti Panici PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giovanni Scambia PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Anna Fagotti PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Fagotti PhD.

Ethics declarations

Disclosures

Claudia Marchetti, Rossella De Leo, Angela Musella, Marco D’Indinosante, Ettore Capoluongo, Angelo Minucci, Pierluigi Benedetti Panici, Giovanni Scambia, and Anna Fagotti declare no conflicts of interest.

Additional information

The original version of this article was revised: the spelling of Angelo Minucci’s last name has been corrected.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 43 kb)

Supplementary material 2 (JPEG 30 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marchetti, C., De Leo, R., Musella, A. et al. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study. Ann Surg Oncol 25, 3701–3708 (2018). https://doi.org/10.1245/s10434-018-6700-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6700-6

Keywords

Search

Navigation